

It is Claimed:

1. A screening method, useful to identify compounds affecting motor function in ALS or MND patients, comprising:
 - 5 administering an anandamide/cannabinoid receptor/acceptor agonist to a mammal having at least one detectable motor function related to an ALS or MND symptom;
 - detecting any motor function change ; and,
 - evaluating any such motor function change with respect to a determinable motor
 - 10 function.
2. A method of screening for compounds useful for promoting normal motor function in ALS patients comprising: (a) administering a compound that is a anandamide/cannabinoid receptor/acceptor agonist to a mammal having observable motor function, and (b) evaluating one or more indicia of motor
- 15 function in said mammal, wherein a compound that promotes normal motor function is identified.
3. A therapeutic method useful for a patient determined to be suffering from one or more abnormal motor symptoms of Amyotrophic Lateral Sclerosis or Motor Neurone Disease, comprising;
 - 20 administering a predetermined amount of an anandamide/cannabinoid receptor/acceptor agonist, the amount administered being effective to promote normal motor function to the patient.
 4. The therapeutic method as in claim 3 wherein the administering is oral, intravenous, inhaled, sub-lingual, or via a patch or a spray,
 - 25